SSShahram Salek-Ardakani

Shahram Salek-Ardakani

*This is an algorithmically generated author record based on publicly available information.

Shahram Salek-Ardakani has a total of 147 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Is Kaposi’s sarcoma the end of the OX40/OX40L axis in atopic dermatitis?

    by Shahram Salek-Ardakani

    The OX40/OX40L axis entered clinical development in atopic dermatitis with a strong biological rationale and early signs of durable activity. However, as the treatment landscape evolved, questions emerged about whether the magnitude of monotherapy benefit was sufficient relative to established and emerging therapies. The discontinuation of rocatinlimab after confirmed and suspected cutaneous Kaposi’s sarcoma cases, together with two cumulative cases reported in the amlitelimab program in patients with known risk factors, has changed the discussion from early promise to mechanism, risk, and therapeutic strategy. Although a causal link between OX40/OX40L modulation and Kaposi’s sarcoma remains unproven, available human genetic and experimental observations make the association biologically plausible but mechanistically unresolved. The central challenge is now to determine how the axis can be targeted, in which patients, and in what therapeutic context, to maximize clinical benefit while managing risk. Rather than signaling the end of the axis in atopic dermatitis, Kaposi’s sarcoma may instead mark the limits of a first-generation development strategy and the beginning of a more selective approach built around molecule design, therapeutic context, and prospective risk mitigation.


  • Open Access

    Editorial: Follicular helper T cells in immunity and autoimmunity, volume II

    by Shahram Salek-Ardakani, Georgia Fousteri, Maria Pia Cicalese

    Despite substantial progress in medicine, there remains an urgent need to address complex diseases through innovative immunological approaches. Over the past decade, follicular CD4⁺ T cell biology has expanded from a germinal center-restricted concept into a broader framework that now spans systemic autoimmunity, infection, and cancer. At its core, this area of study shows that these cells are not fixed types but rather flexible immune responders that conform to the body's needs. Follicular helper T cells (Tfh), classically defined by CXCR5-driven follicular positioning and a transcriptional program centered on BCL6, with high ICOS and PD-1 expression, are essential architects of germinal center dynamics, affinity maturation, and durable humoral immunity. [1][2] In parallel, follicular regulatory T cells (Tfr), which integrate a regulatory lineage with follicular-homing features, have been recognized as critical regulators of this circuitry, restraining excessive B cell and Tfh activity to preserve tolerance. [3][4] More recently, the field has moved beyond canonical follicles to incorporate circulating Tfh states as biomarkers and peripheral helper T cell (Tph) populations as tissue-adapted engines of B cell help in inflamed sites. [5][6] Collectively, these advances have sharpened a unifying message: follicular CD4⁺ T cell programs are not static cell types, but adaptable immunologic states, continuously tuned by antigen burden, tissue damage, metabolic constraints, and microenvironmental context.Volume II of this Research Topic assembles eight articles that reflect this maturation of the field. This volume asks three questions: how are T cell follicular programs wired, when are they constrained, and where do they become clinically actionable? Rather than simply reiterating that Tfh and Tfr "matter," the contributions converge on addressing these key questions. Across infection, autoimmunity, tumor immunology, and Tfh-lineage malignancies, the central theme is that follicular CD4⁺ T cell biology is profoundly context-dependent. That context can be decoded mechanistically, tracked clinically, and potentially manipulated therapeutically.Two studies in this volume underscore that successful humoral immunity during infection is not entirely influenced by classic antigen-presenting and cytokine cues, but also by pathways that sense tissue stress and enforce developmental timing. This insight serves as a lens for vaccine design, showing how these damage-sensing pathways can be leveraged to amplify immune responses and improve clinical outcomes.Russo and colleagues address a clinically meaningful paradox in pediatric RSV: severe disease can coincide with suboptimal antibody quality. By investigating moderate and severe RSV cohorts alongside healthy controls, they link clinical severity to a coordinated signature of impaired circulating Tfh biology, reduced cTfh frequencies, lower systemic IL-21 levels, and weaker neutralizing antibody responses targeting prefusion F (PreF). [7] A key strength of the work is that it does not stop at association; instead, it identifies a plausible mechanistic axis connecting airway tissue damage to impaired helper function. The authors show that extracellular ATP is elevated in severe disease (in both systemic and respiratory compartments) and that cTfh cells exhibit increased expression of the purinergic receptor P2X7R, consistent with elevated responsiveness to a danger-associated metabolite. Functionally, P2X7R stimulation (using BzATP) triggers cTfh apoptosis, blunts proliferative capacity, and suppresses IL-21 production, effects that are at least partially reversed by pharmacologic antagonism. [7] Together, the research suggests a coherent model in which excessive purinergic "danger" signaling during severe RSV acts as a brake on the very CD4⁺ helper compartment required for optimal humoral output, offering a new model for interpreting why antibody responses can be impaired in the setting of intense inflammation. Supporting this "damage-sensing" framework, Zhu and colleagues focus on developmental control across time during chronic viral infection, using LCMV Clone 13 as a model of sustained antigenic stress. [8] Their study positions THEMIS, best known as a T cell-specific adaptor involved in TCR signaling and selection, as a stage-specific regulator of CD4⁺ T cell fate that can both enable and constrain the Tfh program depending on timing. Early after infection, THEMIS supports the expansion and acquisition of Tfh differentiation features in virus-specific CD4⁺ T cells, consistent with a role in allowing follicular commitment under high inflammatory pressure. Strikingly, later in infection, the phenotype shifts: in competitive adoptive transfer settings, Themis-deficient CD4⁺ T cells ultimately generate stronger germinal center responses and higher antiviral IgG levels, accompanied by improved late viral control. [8] Mechanistically, the authors connect this time-dependent switch to regulation of a progenitor-like TCF-1⁺ CD4⁺ pool (often conceptualized as a reservoir for durability), proposing that THEMIS preserves this progenitor state and thereby restrains excessive late skewing toward terminal follicular outcomes. [8] Single-cell transcriptomic analysis at later time points supports a trajectory-level model in which THEMIS shapes the balance between progenitor maintenance and follicular differentiation under chronic antigen pressure. In aggregate, the work reframes chronic infection Tfh biology as a temporally gated process, one that may require early permissive signals but later restraint to optimize long-term immune architecture [8]. A key next step will be determining whether pathways such as ATP-P2X7R signaling and THEMIS-dependent progenitor control are merely correlates of disease severity and chronicity, or whether they can be therapeutically modulated in a time-and tissue-restricted...

  • Top Cited Papers

    Targeting the TNF and TNFR superfamilies in autoimmune disease and cancer

    by Michael Croft, Shahram Salek-Ardakani, Carl F. Ware

    The first anti-tumour necrosis factor (TNF) monoclonal antibody, infliximab (Remicade), celebrated its 25th anniversary of FDA approval in 2023. Inhibitors of TNF have since proved clinically efficacious at reducing inflammation associated with several autoimmune diseases, including rheumatoid arthritis, psoriasis and Crohn’s disease. The success of TNF inhibitors raised unrealistic expectations for targeting other members of the TNF superfamily (TNFSF) of ligands and their receptors, with difficulties in part related to their more limited, variable expression and potential redundancy. However, there has been a resurgence of interest and investment, with many of these cytokines or their cognate receptors now under clinical investigation as targets for modulation of autoimmune and inflammatory diseases, as well as cancer. This Review assesses TNFSF-targeted biologics currently in clinical development for immune system-related diseases, highlighting ongoing challenges and future directions.


  • Top Cited Papers

    Reversing T-cell Exhaustion in Cancer: Lessons Learned from PD-1/PD-L1 Immune Checkpoint Blockade

    by Natalija Budimir, Graham D. Thomas, Joseph S. Dolina, Shahram Salek-Ardakani

    Anti–PD-1/PD-L1 immune checkpoint blockade (ICB) therapy has revolutionized the treatment of many types of cancer over the past decade. The initial therapeutic hypothesis underlying the mechanism of anti–PD-1/PD-L1 ICB was built around the premise that it acts locally in the tumor, reversing the exhaustion of PD-1hiCD8+ T cells by “releasing the brakes.” However, recent studies have provided unprecedented insight into the complexity within the CD8+ T-cell pool in the tumor microenvironment (TME). Single-cell RNA sequencing and epigenetic profiling studies have identified novel cell surface markers, revealing heterogeneity within CD8+ T-cell states classified as unique. Moreover, these studies highlighted that following ICB, CD8+ T-cell states within and outside the TME possess a differential capacity to respond, mobilize to the TME, and seed an effective antitumor immune response. In aggregate, these recent developments have led to a reevaluation of our understanding of both the underlying mechanisms and the sites of action of ICB therapy. Here, we discuss the evidence for the reversibility of CD8+ T-cell exhaustion after ICB treatment and its implication for the further development of cancer immunotherapy.


  • Open Access

    Combinatorial immunotherapy induces tumor-infiltrating CD8+ T cells with distinct functional, migratory, and stem-like properties

    by Natalija Van Braeckel-Budimir, Joseph Samuel Dolina, Jie Wei, Xiao Wang, Shih-Hsun Chen, Pamela Santiago, Guanghuan Tu, Luca Micci, Amir A Al-Khami, Sophia Pfister, et al.

    Background: Programmed death (ligand) 1 (PD-(L)1) blockade and OX40/4-1BB costimulation have been separately evaluated in the clinic to elicit potent antitumor T cell responses. The precise mechanisms underlying single agent activity are incompletely understood. It also remains unclear if combining individual therapies leads to synergism, elicits novel immune mechanisms, or invokes additive effects. Methods: We performed high-dimensional flow cytometry and single-cell RNA sequencing-based immunoprofiling of murine tumor-infiltrating lymphocytes (TILs) isolated from hosts bearing B16 or MC38 syngeneic tumors. This baseline infiltrate was compared to TILs after treatment with either anti-PD-(L)1, anti-OX40, or anti-4-1BB as single agents or as double and triple combinatorial therapies. Fingolimod treatment and CXCR3 blockade were used to evaluate the contribution of intratumoral versus peripheral CD8+ T cells to therapeutic efficacy. Results: We identified CD8+ T cell subtypes with distinct functional and migratory signatures highly predictive of tumor rejection upon treatment with single agent versus combination therapies. Rather than reinvigorating terminally exhausted CD8+ T cells, OX40/4-1BB agonism expanded a stem-like PD-1loKLRG-1+Ki-67+CD8+ T cell subpopulation, which PD-(L)1 blockade alone did not. However, PD-(L)1 blockade synergized with OX40/4-1BB costimulation by dramatically enhancing stem-like TIL presence via a CXCR3-dependent mechanism. Conclusions: Our findings provide new mechanistic insights into the interplay between components of combinatorial immunotherapy, where agonism of select costimulatory pathways seeds a pool of stem-like CD8+ T cells more responsive to immune checkpoint blockade (ICB).


  • Open Access

    EZH2 Inhibition Compromises α4-1BB-Mediated Antitumor Efficacy by Reducing the Survival and Effector Programming of CD8+ T Cells

    by Christopher J. Stairiker, Sophia Xiao Pfister, Eleanore Hendrickson, Wenjing Yang, Tao Xie, Catherine Lee, Haikuo Zhang, Christopher Dillon, Graham D. Thomas, Shahram Salek-Ardakani

    Enhancer of Zeste Homolog 2 (EZH2) inhibitors (EZH2i) are approved to treat certain cancer types. Previous studies have suggested the potential to combine EZH2i with immune checkpoint blockade targeting coinhibitory receptors like PD-(L)1 and CTLA-4, but whether it can also enhance the activity of agents targeting costimulatory receptors is not known. Here, we explore the combination between EZH2i and an agonist antibody targeting the T cell costimulatory receptor 4-1BB (α4-1BB). Our data show that EZH2i compromise the efficacy of α4-1BB in both CT26 colon carcinoma and in an in vivo protein immunization model. We link this to reduced effector survival and increased BIM expression in CD8+ T cells upon EZH2i treatment. These data support the requirement of EZH2 function in 4-1BB-mediated CD8+ T cell expansion and effector programming and emphasize the consideration that must be given when combining such antitumoral therapies.


  • Open Access

    Dual checkpoint blockade of CD47 and PD-L1 using an affinity-tuned bispecific antibody maximizes antitumor immunity

    by Shih-Hsun Chen, Pawel K Dominik, Jessica Stanfield, Sheng Ding, Wenjing Yang, Nadia Kurd, Ryan Llewellyn, Jonathan Heyen, Carole Wang, Zea Melton, et al.

    Background: T cell checkpoint immunotherapies have shown promising results in the clinic, but most patients remain non-responsive. CD47-signal regulatory protein alpha (SIRPα) myeloid checkpoint blockade has shown early clinical activity in hematologic malignancies. However, CD47 expression on peripheral blood limits αCD47 antibody selectivity and thus efficacy in solid tumors. Methods: To improve the antibody selectivity and therapeutic window, we developed a novel affinity-tuned bispecific antibody targeting CD47 and programmed death-ligand 1 (PD-L1) to antagonize both innate and adaptive immune checkpoint pathways. This PD-L1-targeted CD47 bispecific antibody was designed with potent affinity for PD-L1 and moderate affinity for CD47 to achieve preferential binding on tumor and myeloid cells expressing PD-L1 in the tumor microenvironment (TME). Results: The antibody design reduced binding on red blood cells and enhanced selectivity to the TME, improving the therapeutic window compared with αCD47 and its combination with αPD-L1 in syngeneic tumor models. Mechanistically, both myeloid and T cells were activated and contributed to antitumor activity of αCD47/PD-L1 bispecific antibody. Distinct from αCD47 and αPD-L1 monotherapies or combination therapies, single-cell RNA sequencing (scRNA-seq) and gene expression analysis revealed that the bispecific treatment resulted in unique innate activation, including pattern recognition receptor-mediated induction of type I interferon pathways and antigen presentation in dendritic cells and macrophage populations. Furthermore, treatment increased the Tcf7+ stem-like progenitor CD8 T cell population in the TME and promoted its differentiation to an effector-like state. Consistent with mouse data, the compounds were well tolerated and demonstrated robust myeloid and T cell activation in non-human primates (NHPs). Notably, RNA-seq analysis in NHPs provided evidence that the innate activation was mainly contributed by CD47-SIRPα but not PD-L1-PD-1 blockade from the bispecific antibody. Conclusion: These findings provide novel mechanistic insights into how myeloid and T cells can be uniquely modulated by the dual innate and adaptive checkpoint antibody and demonstrate its potential in clinical development (NCT04881045) to improve patient outcomes over current PD-(L)1 and CD47-targeted therapies.


  • Open Access

    Intra-Tumoral Activation of Endosomal TLR Pathways Reveals a Distinct Role for TLR3 Agonist Dependent Type-1 Interferons in Shaping the Tumor Immune Microenvironment

    by Graham Thomas, Luca Micci, Wenjing Yang, Joseph Katakowski, Cecilia Oderup, Purnima Sundar, Xiao Wang, Kenneth G. Geles, Shobha Potluri, Shahram Salek-Ardakani

    Toll-like receptor (TLR) agonists have received considerable attention as therapeutic targets for cancer immunotherapy owing to their ability to convert immunosuppressive tumor microenvironments towards a more T-cell inflamed phenotype. However, TLRs differ in their cell expression profiles and intracellular signaling pathways, raising the possibility that distinct TLRs differentially influence the tumor immune microenvironment. Using single-cell RNA-sequencing, we address this by comparing the tumor immune composition of B16F10 melanoma following treatment with agonists of TLR3, TLR7, and TLR9. Marked differences are observed between treatments, including decreased tumor-associated macrophages upon TLR7 agonist treatment. A biased type-1 interferon signature is elicited upon TLR3 agonist treatment as opposed to a type-2 interferon signature with TLR9 agonists. TLR3 stimulation was associated with increased macrophage antigen presentation gene expression and decreased expression of PD-L1 and the inhibitory receptors Pirb and Pilra on infiltrating monocytes. Furthermore, in contrast to TLR7 and TLR9 agonists, TLR3 stimulation ablated FoxP3 positive CD4 T cells and elicited a distinct CD8 T cell activation phenotype highlighting the potential for distinct synergies between TLR agonists and combination therapy agents.


  • Top Cited Papers
    Open Access

    CD8+ T Cell Exhaustion in Cancer

    by Joseph S. Dolina, Natalija Van Braeckel-Budimir, Graham D. Thomas, Shahram Salek-Ardakani

    A paradigm shift in the understanding of the exhausted CD8+ T cell (Tex) lineage is underway. Originally thought to be a uniform population that progressively loses effector function in response to persistent antigen, single-cell analysis has now revealed that CD8+ Tex is composed of multiple interconnected subpopulations. The heterogeneity within the CD8+ Tex lineage is comprised of immune checkpoint blockade (ICB) permissive and refractory subsets termed stem-like and terminally differentiated cells, respectively. These populations occupy distinct peripheral and intratumoral niches and are characterized by transcriptional processes that govern transitions between cell states. This review presents key findings in the field to construct an updated view of the spatial, transcriptional, and functional heterogeneity of anti-tumoral CD8+ Tex. These emerging insights broadly call for (re-)focusing cancer immunotherapies to center on the driver mechanism(s) underlying the CD8+ Tex developmental continuum aimed at stabilizing functional subsets.


  • Open Access

    CXCL9-expressing tumor-associated macrophages: new players in the fight against cancer

    by Paola Marie Marcovecchio, Graham Thomas, Shahram Salek-Ardakani

    Tumor-associated macrophages (TAMs) are among the main contributors to immune suppression in the tumor microenvironment, however, TAM depletion strategies have yielded little clinical benefit. Here, we discuss the concept that TAMs are also key regulators of anti-PD(L)-1-mediated CD8 T cell-dependent immunity. Emerging data suggest that expression of the chemokine CXCL9 by TAMs regulates the recruitment and positioning of CXCR3-expressing stem-like CD8 T (Tstem) cells that underlie clinical responses to anti-PD(L)-1 treatment. We evaluate clinical and mechanistic studies that establish relationships between CXCL9-expressing TAMs, Tstem and antitumor immunity. Therapies that enhance anti-PD(L)-1 response rates must consider TAM CXCL9 expression. In this perspective, we discuss opportunities to enhance the frequency and function of CXCL9 expressing TAMs and draw on comparative analyzes from infectious disease models to highlight potential functions of these cells beyond Tstem recruitment.